BR112023001330A2 - N'-(2-CHLORO-6-METHYLBENZOYL)-4-METHYL-3-[2-(3-QUINOLYL)ETHYNYL]-BENZOHYDRAZIDE FOR TREATMENT OF ALZHEIMER'S DISEASE - Google Patents
N'-(2-CHLORO-6-METHYLBENZOYL)-4-METHYL-3-[2-(3-QUINOLYL)ETHYNYL]-BENZOHYDRAZIDE FOR TREATMENT OF ALZHEIMER'S DISEASEInfo
- Publication number
- BR112023001330A2 BR112023001330A2 BR112023001330A BR112023001330A BR112023001330A2 BR 112023001330 A2 BR112023001330 A2 BR 112023001330A2 BR 112023001330 A BR112023001330 A BR 112023001330A BR 112023001330 A BR112023001330 A BR 112023001330A BR 112023001330 A2 BR112023001330 A2 BR 112023001330A2
- Authority
- BR
- Brazil
- Prior art keywords
- benzohydrazide
- methylbenzoyl
- quinolyl
- ethynyl
- chloro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
N ¢-(2-CLORO-6-METILBENZOIL)-4-METIL-3-[2-(3-QUINOLIL)ETINIL]- BENZOHIDRAZIDA PARA TRATAMENTO DA DOENÇA DE ALZHEIMER. A presente invenção fornece um método para prevenir ou tratar a doença de Alzheimer e sintomas da mesma compreendendo a administração a um indivíduo em necessidade de uma quantidade terapeuticamente eficaz de N'-(2-cloro-6-metilbenzoil)-4-metil-3-[2-(3-quinolil)etinil]-benzohidrazida ou sais farmaceuticamente aceitáveis do mesmo, em que a prevenção e/ou tratamento da referida doença e sintomas da mesma é alcançado pela inibição de beta-amiloide (Aß) agregação de placa, hiperfosforilação de tau, c-Abl quinase ou uma combinação destes. Também é divulgado o uso de uma quantidade terapeuticamente eficaz de N'-(2-cloro-6-metilbenzoil)-4-metil-3-[2-(3-quinolil)etinil]-benzohidrazida ou sais farmaceuticamente aceitáveis do mesmo para inibir a agregação de placa beta-amiloide (Aß), hiperfosforilação de tau, c-Abl quinase ou uma combinação destes.N ¢-(2-CHLORO-6-METHYLBENZOYL)-4-METHYL-3-[2-(3-QUINOLYL)ETHYNYL]-BENZOHYDRAZIDE FOR TREATMENT OF ALZHEIMER'S DISEASE. The present invention provides a method of preventing or treating Alzheimer's disease and symptoms thereof comprising administering to a subject in need of it a therapeutically effective amount of N'-(2-chloro-6-methylbenzoyl)-4-methyl-3 -[2-(3-quinolyl)ethynyl]-benzohydrazide or pharmaceutically acceptable salts thereof, wherein the prevention and/or treatment of said disease and symptoms thereof is achieved by inhibiting beta-amyloid (Aß) plaque aggregation, hyperphosphorylation of tau, c-Abl kinase or a combination thereof. Also disclosed is the use of a therapeutically effective amount of N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide or pharmaceutically acceptable salts thereof to inhibit beta-amyloid (Aß) plaque aggregation, tau hyperphosphorylation, c-Abl kinase, or a combination thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202021032951 | 2020-07-31 | ||
PCT/IB2021/056986 WO2022024072A1 (en) | 2020-07-31 | 2021-07-30 | N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl) ethynyl]-benzohydrazide for treatment of alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023001330A2 true BR112023001330A2 (en) | 2023-02-14 |
Family
ID=77265130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023001330A BR112023001330A2 (en) | 2020-07-31 | 2021-07-30 | N'-(2-CHLORO-6-METHYLBENZOYL)-4-METHYL-3-[2-(3-QUINOLYL)ETHYNYL]-BENZOHYDRAZIDE FOR TREATMENT OF ALZHEIMER'S DISEASE |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230301982A1 (en) |
EP (1) | EP4188351A1 (en) |
JP (1) | JP2023536440A (en) |
KR (1) | KR20230047140A (en) |
CN (1) | CN116194098A (en) |
AU (1) | AU2021317186A1 (en) |
BR (1) | BR112023001330A2 (en) |
CA (1) | CA3185939A1 (en) |
CL (1) | CL2023000270A1 (en) |
IL (1) | IL300044A (en) |
MX (1) | MX2023001358A (en) |
WO (1) | WO2022024072A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023214314A1 (en) | 2022-05-02 | 2023-11-09 | Sun Pharma Advanced Research Company Limited | Vodobatinib for reducing progression of parkinson's disease |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5905028B2 (en) | 2011-01-21 | 2016-04-20 | スン プハルマ アドバンセド リサーチ カンパニー リミテド | Tyrosine kinase inhibitors containing diarylacetylene hydrazides |
WO2017208267A1 (en) | 2016-06-02 | 2017-12-07 | Sun Pharma Advanced Research Company Limited | Treatment for parkinson's disease |
JP7234129B2 (en) * | 2017-03-15 | 2023-03-07 | サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド | A novel amorphous dispersion of 4-methyl-3-quinolin-3-ylethynyl-benzoic acid N'-(2-chloro-6-methyl-benzoyl)hydrazide |
-
2021
- 2021-07-30 AU AU2021317186A patent/AU2021317186A1/en active Pending
- 2021-07-30 EP EP21752214.3A patent/EP4188351A1/en active Pending
- 2021-07-30 CN CN202180061409.2A patent/CN116194098A/en active Pending
- 2021-07-30 US US18/018,438 patent/US20230301982A1/en active Pending
- 2021-07-30 IL IL300044A patent/IL300044A/en unknown
- 2021-07-30 BR BR112023001330A patent/BR112023001330A2/en unknown
- 2021-07-30 MX MX2023001358A patent/MX2023001358A/en unknown
- 2021-07-30 CA CA3185939A patent/CA3185939A1/en active Pending
- 2021-07-30 JP JP2023505420A patent/JP2023536440A/en active Pending
- 2021-07-30 KR KR1020237006846A patent/KR20230047140A/en unknown
- 2021-07-30 WO PCT/IB2021/056986 patent/WO2022024072A1/en active Application Filing
-
2023
- 2023-01-27 CL CL2023000270A patent/CL2023000270A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021317186A1 (en) | 2023-03-16 |
KR20230047140A (en) | 2023-04-06 |
CL2023000270A1 (en) | 2023-09-29 |
IL300044A (en) | 2023-03-01 |
WO2022024072A1 (en) | 2022-02-03 |
JP2023536440A (en) | 2023-08-25 |
CA3185939A1 (en) | 2022-02-03 |
EP4188351A1 (en) | 2023-06-07 |
CN116194098A (en) | 2023-05-30 |
MX2023001358A (en) | 2023-02-27 |
US20230301982A1 (en) | 2023-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022026899A2 (en) | COMPOUND REPRESENTED BY FORMULA (I) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OR PREVENTION OF A VIRAL INFECTION, METHOD OF INHIBITING VIRAL PROTEASE 3C OR VIRAL PROTEASE 3CL IN A MAMMAL, AND METHOD OF TREATMENT OF A DISORDER RESPIRATORY | |
Olszewski | Episodic dermatolymphangioadenitis (DLA) in patients with lymphedema of the lower extremities before and after administration of benzathine penicillin: a preliminary study | |
BR112017017009A2 (en) | uses of a formaldehyde scavenger and pharmaceutical composition, methods for preventing, delaying, slowing or slowing transformation of a compound and for treating cancer, and pharmaceutical composition. | |
BR112018016001A2 (en) | pharmaceutical composition, treatment methods and uses thereof | |
BR112022009571A2 (en) | USE OF FAK INHIBITOR IN THE PREPARATION OF A DRUG TO TREAT TUMORS THAT HAVE NRAS MUTATION | |
BR112022025805A2 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND METHOD FOR TREAT OR PREVENT A DISORDER, CONDITION OR DISEASE | |
BR112015029491A2 (en) | imidazopyrrolidinone derivatives and their use in the treatment of disease | |
BR112023002573A2 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OR PREVENTION OF VIRAL INFECTION AND RESPIRATORY DISORDERS AND METHOD OF INHIBITION OF VIRAL PROTEASE | |
NO20090887L (en) | Procedure for treating and preventing mucositis | |
BR112021024491A2 (en) | Immunogenic composition, and method of preventing, treating or ameliorating an infection, disease or condition | |
BR112021017314A2 (en) | USE OF ELAEOCARPUS SYLVESTRIS EXTRACT | |
BRPI0415953A (en) | oral controlled release dosage formulation, method of treating a disorder, set of controlled release dosage forms and method for administering the formulation | |
BR112021021637A2 (en) | Subunit vaccine for treating or preventing a respiratory tract infection | |
BR112023001330A2 (en) | N'-(2-CHLORO-6-METHYLBENZOYL)-4-METHYL-3-[2-(3-QUINOLYL)ETHYNYL]-BENZOHYDRAZIDE FOR TREATMENT OF ALZHEIMER'S DISEASE | |
BR112021024845A2 (en) | Combination for the treatment of infections caused by mycoplasma genitalium | |
BR112018017233A2 (en) | i use. butyriciproducens and / or e. hallii and composition | |
CL2023001992A1 (en) | Anti-n3pglu beta amyloid antibodies and their uses | |
BR112019002945A2 (en) | Combination therapy for pancreatic cancer treatment | |
BR112018072298A2 (en) | treatment of Zika virus infections using alpha-glucosidase inhibitors | |
BR112014004339A2 (en) | oral suspension | |
BR112018010497A2 (en) | synergistic combination of pyrrolidone carboxylic acid and / or its salts and hyaluronic acid and / or its salts for use in the treatment and / or prevention of mucosal dryness and irritation and related pharmaceutical formulations | |
Wollina et al. | Pharmacotherapy of pompholyx | |
BR112023001547A2 (en) | PHARMACEUTICAL COMPOSITION COMPRISING LIRAGLUTIDE, OR GEFITINIB OR ONE OF THEIR SALTS OR SOLVATES, AND USE THEREOF | |
BR112018072164A2 (en) | pharmaceutical composition, method for treating and / or preventing a patient's skin disease and / or alleviating the symptoms thereof, and cosmetic use of a composition | |
BR112022019338A2 (en) | MIGRAINE PREVENTIVE TREATMENT |